De-Risked Oncology Targets with Assets from Checkpoint Therapeutics

Update: 2022-11-04

Description

James Oliviero, CEO of Checkpoint Therapeutics, is certain that fortunes can be won by building better and cheaper mousetraps. That’s why he is positioned to capture significant market share with assets for the de-risked oncology targets of PD-L1, with Cosibelimab, and EGFR with Olafertinib. For Cosibelimab, an anti-PD-L1 antibody, Checkpoint offers an improved mechanism of action and a lower price point. For Olafertinib, a 3rd generation EGFR inhibitor, the play is a better tolerability profile that will boost patient compliance. Building better traps—that’s the bottom line.

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Leveraging AI and ML in Drug R&D: Current and Future Impacts to the Life Sciences Industry

2023-10-0341:00

LifeSci Search Podcast: Episode #1

2023-03-1737:54

Regenerative Medicine from Humacyte: Off-the-Shelf, Human-Sourced Acellular Vessels for Traumatic Wound Repair

2023-02-1036:04

A Brief Chat with Erez Raphael, CEO of DarioHealth

2023-01-0617:41

Onconova – Developing Best-in-class Anti-cancer Agents with Multi-faceted MOAs

2023-01-0530:42

A Brief Chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc.

2023-01-0409:51

A Brief Chat with Martin Welschof, CEO of BioInvent

2023-01-0317:22

A Brief Chat with Raphi Levy, CFO of Alpha Tau Medical Ltd.

2022-12-2911:19

A Brief Chat with Amir London, CEO of Kamada Ltd.

2022-12-2813:30

A Brief Chat with Rob Etherington, President & CEO of Clene, Inc.

2022-12-2714:36

Helping the Body Help Itself with EscharEx: The Next Generation Wound-Care Therapeutic from MediWound

2022-12-1626:38

A Promising New Immune Checkpoint from Sensei Bio: VISTA

2022-12-1333:29

Turning Amino Acids into Drugs: A Novel Platform from Axcella Health

2022-12-0843:01

Lipocine Inc’s Formulation for Success: Oral Agents for CNS Disorders

2022-11-1727:01

89bio Aims to Tame NASH and Severe Hypertriglyceridemia (SHTG) with Lead Asset Pegozafermin

2022-11-1134:53

De-Risked Oncology Targets with Assets from Checkpoint Therapeutics

2022-11-0435:44

Deep Transcranial Magnetic Stimulation (Deep TMS™): BrainsWay’s Innovative and Non-Invasive Therapy for Major Depressive Disorder, Anxious Depression, OCD, and Smoking Addiction

2022-10-2042:11

An Oncology Update on CDK 2/9 Inhibition: Cyclacel Pharmaceuticals

2022-09-2935:22

Oncology on the Move—Artios: Financing Considerations for an Early Biotech

2022-09-1926:55

Fire Up the Immune System to Lead the Charge Against Cancer: Alligator Bioscience

2022-09-1526:46